Shares of Sarepta Therapeutics (SRPT) rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals .ARWR Deal Expands Sarepta’s PipelinePer the deal terms, Sarepta will acquire exclusive rights to Arrowhead’s seven pipeline programs, which include four in active clinical development and the remaining three in preclinical development. These programs are being developed against a broad range of genetic diseases in ...